DNA repair protein XRCC4

From Wikipedia, the free encyclopedia
  (Redirected from XRCC4)
Jump to: navigation, search
X-ray repair complementing defective repair in Chinese hamster cells 4
Protein XRCC4 PDB 1fu1.png
PDB rendering based on 1fu1.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbol XRCC4
External IDs OMIM194363 MGI1333799 HomoloGene2555 GeneCards: XRCC4 Gene
RNA expression pattern
PBB GE XRCC4 205072 s at tn.png
PBB GE XRCC4 205071 x at tn.png
PBB GE XRCC4 210813 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 7518 108138
Ensembl ENSG00000152422 ENSMUSG00000021615
UniProt Q13426 Q924T3
RefSeq (mRNA) NM_003401 NM_028012
RefSeq (protein) NP_003392 NP_082288
Location (UCSC) Chr 5:
82.37 – 82.65 Mb
Chr 13:
89.77 – 90.09 Mb
PubMed search [1] [2]

DNA repair protein XRCC4 also known as X-ray repair cross-complementing protein 4 or XRCC4 is a protein that in humans is encoded by the XRCC4 gene. In addition to humans, the XRCC4 protein is also expressed in many other metazoans, fungi and in plants.[1] The X-ray repair cross-complementing protein 4 is one of several core proteins involved in the non-homologous end joining (NHEJ) pathway to repair DNA double strand breaks (DSBs).[2][3][4]

NHEJ requires two main components to achieve successful completion. The first component is the cooperative binding and phosphorylation of artemis by the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs). Artemis cleaves the ends of damaged DNA to prepare it for ligation. The second component involves the bridging of DNA to DNA Ligase IV (LigIV), by XRCC4, with the aid of Cernunos-XLF. DNA-PKcs and XRCC4 are anchored to Ku70 / Ku80 heterodimer, which are bound to the DNA ends.[5]

Since XRCC4 is the key protein that enables interaction of LigIV to damaged DNA and therefore ligation of the ends, mutations in the XRCC4 gene were found to cause embryonic lethality in mice and developmental inhibition and immunodeficiency in humans.[5] Furthermore certain mutations in the XRCC4 gene are associated with an increased risk of cancer.[6]

Double strand breaks[edit]

Main article: double strand breaks

DSBs are mainly caused by free radicals generated from ionizing radiation in the environment and from by-products released continually during cellular metabolism. DSBs that are not efficiently repaired may result in the loss of important protein coding genes and regulatory sequences required for gene expression necessary for the life of a cell.[4][7] DSBs that cannot rely on a newly copied sister chromosome generated by DNA replication to fill in the gap will go into the NHEJ pathway. This method of repair is essential as it is a last resort to prevent loss of long stretches of the chromosome.[4][8] NHEJ is also used to repair DSBs generated during V(D)J recombination when gene regions are rearranged to create the unique antigen binding sites of antibodies and T-cell receptors.[4]

Sources of DNA damage[edit]

DNA damage occurs very frequently and is generated from exposure to a variety of both exogenous and endogenous genotoxic sources.[7] One of these include ionizing radiation, such as γ radiation and X-rays, which ionize the deoxyribose groups in the DNA backbone and can induce DSBs.[4] Reactive oxygen species, ROS, such as superoxide (O2– • ), hydrogen peroxide (H2O2), hydroxyl radicals (HO), and singlet oxygen (1O2), can also produce DSBs as a result of ionizing radiation as well as cellular metabolic processes that are naturally occurring.[9] DSBs can also be caused by the action of DNA polymerase while attempting to replicate DNA over a nick that was introduced as a result of DNA damage.[4][7]

Consequences of DSBs[edit]

There are many types of DNA damage, but DSBs, in particular, are the most harmful as both strands are completely disjointed from the rest of the chromosome. If an efficient repair mechanism does not exist, the ends of the DNA can eventually degrade, leading to a permanent loss of sequence.[4] A double-stranded gap in DNA will also prevent replication from proceeding, resulting in an incomplete copy of that specific chromosome, targeting the cell for apoptosis. As with all DNA damage, DSBs can introduce new mutations that can ultimately lead to cancer.[4][7]

DSB repair methods[edit]

There are two methods for repairing DSBs depending on when the damage occurs during mitosis.[2] If the DSB occurs after DNA replication has completed proceeding S phase of the cell cycle, the DSB repair pathway will use homologous recombination by pairing with the newly synthesized daughter strand to repair the break. However, if the DSB is generated prior to synthesis of the sister chromosome, then the template sequence that is required will be absent.[4] For this circumstance, the NHEJ pathway provides a solution for repairing the break and is the main system used to repair DSBs in humans and multicellular eukaryotes.[2][4][5][9] During NHEJ, very short stretches of complementary DNA, 1 bp or more at a time, are hybridized together, and the overhangs are removed. As a result, this specific region of the genome is permanently lost and the deletion can lead to cancer and premature aging.[4][8]

Properties[edit]

Gene and protein[edit]

The human XRCC4 gene is located on chromosome 5, specifically at 5q14.2. This gene contains eight exons and three mRNA transcript variants, which encode two different protein isoforms. Transcript variant 1, mRNA, RefSeq NM_003401.3, is 1688 bp long and is the shortest out of the three variants. It is missing a short sequence in the 3’ coding region as compared to variant 2. Isoform 1 contains 334 amino acids. Transcript variant 2, mRNA, RefSeq NM_022406, is 1694 bp long and encodes the longest isoform 2, which contains 336 amino acids. Transcript variant 3, RefSeq NM_022550.2, is 1735 bp and is the longest, but it also encodes for the same isoform 1 as variant 1. It contains an additional sequence in the 5’UTR of the mRNA transcript and lacks a short sequence in the 3’ coding region as compared to variant 2.[10]

Structure[edit]

XRCC4
Identifiers
Symbol XRCC4
Pfam PF06632
InterPro IPR010585
SCOP 1fu1
SUPERFAMILY 1fu1

XRCC4 protein is a tetramer that resembles the shape of a dumbbell containing two globular ends separated by a long, thin stalk. The tetramer is composed of two dimers, and each dimer is made up of two similar subunits. The first subunit (L) contains amino acid residues 1 – 203 and has a longer stalk than the second subunit (S) which contains residues 1 – 178.

The globular N-terminal domains of each subunit are identical. They are made up of two, antiparallel beta sheets that face each other in a beta sandwich-like structure (i.e., a "flattened" beta barrel) and are separated by two alpha helices on one side. The N-terminus begins with one beta sheet composed of strands 1, 2, 3, and 4, followed by a helix-turn-helix motif of the two alpha helices, αA and αB, which continues into strands 5, 6, 7, and ending with one alpha-helical stalk at the C-terminus. αA and αB are perpendicular to one another, and because one end of αB is partially inserted between the two beta sheets, it causes them to flare out away from each other. The beta sandwich structure is held together through three hydrogen bonds between antiparallel strands 4 and 7 and one hydrogen bond between strands 1 and 5.

The two helical stalks between subunits L and S intertwine with a single left-handed crossover into a coiled-coil at the top, near the globular domains forming a palm tree configuration. This region interacts with the two alpha helices of the second dimer in an opposite orientation to form a four-helix bundle and the dumbbell-shaped tetramer.[11]

Post-translational modifications[edit]

In order for XRCC4 to be sequestered from the cytoplasm to the nucleus to repair a DSB during NHEJ or to complete V(D)J recombination, post-translational modification at lysine 210 with a small ubiquitin-related modifier (SUMO), or sumoylation, is required. SUMO modification of diverse types of DNA repair proteins can be found in topoisomerases, base excision glycosylase TDG, Ku70/80, and BLM helicase. A common conserved motif is typically found to be a target of SUMO modification, ΨKXE (where Ψ is a bulky, hydrophobic amino acid). In the case of the XRCC4 protein, the consensus sequence surrounding lysine 210 is IKQE. Chinese hamster ovary cells, CHO, that express the mutated form of XRCC4 at K210 cannot be modified with SUMO, fail recruitment to the nucleus and instead accumulate in the cytoplasm. Furthermore, these cells are radiation sensitive and do not successfully complete V(D)J recombination.[3]

Interactions[edit]

Interaction of XRCC4 with other components of the NHEJ complex

Upon generation of a DSB, Ku proteins will move through the cytoplasm until they find the site of the break and bind to it.[12] Ku recruits XRCC4 and Cer-XLF and both of these proteins interact cooperatively with one another through specific residues to form a nucleoprotein pore complex that wraps around DNA. Cer-XLF is a homodimer that is very similar to XRCC4 in the structure and size of its N-terminal and C-terminal domains. Residues arginine 64, leucine 65, and leucine 115 in Cer-XLF interact with lysines 65 and 99 in XRCC4 within their N-terminal domains. Together they form a filament bundle that wraps around DNA in an alternating pattern. Hyper-phosphorylation of the C-terminal alpha helical domains of XRCC4 by DNA-PKcs facilitates this interaction. XRCC4 dimer binds to a second dimer on an adjacent DNA strand to create a tetramer for DNA bridging early on in NHEJ. Prior to ligation, Lig IV binds to the C-terminal stalk of XRCC4 at the site of the break and displaces the second XRCC4 dimer.[5] The BRCT2 domain of Lig IV hydrogen bonds with XRCC4 at this domain through multiple residues and introduces a kink in the two alpha helical tails. The helix-loop-helix clamp connected to the BRCT-linker also makes extensive contacts.[13]

Mechanism[edit]

NHEJ[edit]

The process of NHEJ involves XRCC4 and a number of tightly coupled proteins acting in concert to repair the DSB. The system begins with the binding of one heterodimeric protein called Ku70/80 to each end of the DSB to maintain them close together in preparation for ligation and prevent their degradation.[4][14] Ku70/80 then sequesters one DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to the DNA ends to enable the binding of Artemis protein to one end of each DNA-PKcs.[4][5][13] One end of the DNA-PKcs joins to stabilize the proximity of the DSB and allow very short regions of DNA complementarity to hybridize.[4][5] DNA-PKcs then phosphorylates Artemis at a serine/threonine to activate its exonuclease activity and cleave nucleotides at the single strand tails that are not hybridized in a 5’ to 3’ direction.[4][13] Two XRCC4 proteins are post-translationally modified for recognition and localization to Ku70/80 (5). The two XRCC4 proteins dimerize together and bind to Ku70/80 at the ends of the DNA strands to promote ligation. XRCC4 then forms a strong complex with DNA ligase IV, LigIV, which is enhanced by Cernunnos XRCC4-like factor, Cer-XLF.[5][13] Cer-XLF only binds to XRCC4 without direct interaction with LigIV. LigIV then joins the DNA ends by catalyzing a covalent phosphodiester bond.[4][13]

V(D)J recombination[edit]

V(D)J recombination is the rearrangement of multiple, distinct gene segments in germ-line DNA to produce the unique protein domains of immune cells, B cells and T cells, that will specifically recognize foreign antigens such as viruses, bacteria, and pathogenic eukaryotes. B cells produce antibodies that are secreted into the bloodstream and T cells produce receptors that once translated are transported to the outer lipid bilayer of the cell. Antibodies are composed of two light and two heavy chains. The antigen binding site consists of two variable regions, VL and VH. The remainder of the antibody structure is made up of constant regions, CL, CH, CH2 and CH3. The Kappa locus in the mouse encodes an antibody light chain and contains approximately 300 gene segments for the variable region, V, four J segments than encode a short protein region, and one constant, C, segment. To produce a light chain with one unique type of VL, when B cells are differentiating, DNA is rearranged to incorporate a unique combination of the V and J segments. RNA splicing joins the recombined region with the C segment. The heavy chain gene also contain numerous diversity segments, D, and multiple constant segments, Cμ, Cδ, Cγ, Cε, Cα. Recombination occurs in a specific region of the gene that is located between two conserved sequence motifs called recombination signal sequences. Each motif is flanked by a 7 bp and 9 bp sequence that is separated by a 12 bp spacer, referred to as class 1, or a 23 bp spacer, referred to as class 2. A recombinase made up of RAG1 and RAG2 subunits always cleave between these two sites. The cleavage results in two hairpin structures for the V and J segments, respectively, and the non-coding region, are now separated from the V and J segments by a DSB. The hairpin coding region goes through the process of NHEJ where the closed end is cleaved and repaired. The non-coding region is circularized and degraded.[2][4] Thus, NHEJ is also important in the development of the immune system via its role in V(D)J recombination.[15]

Pathology[edit]

Recent studies have shown an association between XRCC4 and potential susceptibility to a variety of pathologies. The most frequently observed linkage is between XRCC4 mutations and susceptibility to cancers such as bladder cancer, breast cancer, and lymphomas. Studies have also pointed to a potential linkage between XRCC4 mutation and endometriosis. Autoimmunity is also being studied in this regard. Linkage between XRCC4 mutations and certain pathologies may provide a basis for diagnostic biomarkers and, eventually, potential development of new therapeutics.

Cancer susceptibility[edit]

XRCC4 polymorphisms have been linked to a risk of susceptibility for cancers such as bladder cancer,[16] breast cancer,[17] prostate cancer, hepatocellular carcinoma, lymphomas, and multiple myeloma.[18] With respect to bladder cancer, for example, the link between XRCC4 and risk of cancer susceptibility was based on hospital-based case-control histological studies of gene variants of both XRCC4 and XRCC3 and their possible association with risk for urothelial bladder cancer. The linkage with risk for urothelial bladder cancer susceptibility was shown for XRCC4, but not for XRCC3[16] With regard to breast cancer, the linkage with "increased risk of breast cancer" was based on an examination of functional polymorphisms of the XRCC4 gene carried out in connection with a meta-analysis of five case-control studies .[17] There is also at least one hospital-based case-control histological study indicating that polymorphisms in XRCC4 may have an "influence" on prostate cancer susceptibility.[19] Conditional (CD21-cre-mediated) deletion of the XRCC4 NHEJ gene in p53-deficient peripheral mouse B cells resulted in surface Ig-negative B-cell lymphomas, and these lymphomas often had a "reciprocal chromosomal translocation" fusing IgH to Myc (and also had "large chromosomal deletions or translocations" involving IgK or IgL, with IgL "fusing" to oncogenes or to IgH).[20] XRCC4- and p53-deficient pro-B lymphomas "routinely activate c-myc by gene amplification"; and furthermore, it should be noted that XRCC4- and p53-deficient peripheral B-cell lymphomas "routinely ectopically activate" a single copy of c-myc.[20] Indeed, in view of the observation by some that “DNA repair enzymes are correctives for DNA damage induced by carcinogens and anticancer drugs”,[21] it should not be surprising that “SNPs in DNA repair genes may play an important part” in cancer susceptibility.[21] In addition to the cancers identified above, XRCC4 polymorphisms have been identified as having a potential link to various additional cancers such as oral cancer, lung cancer, gastric cancer, and gliomas.[21]

Autoimmunity[edit]

Based on the findings that (1) several polypeptides in the NHEJ pathway are "potential targets of autoantibodies" and (2) "one of the autoimmune epitopes in XRCC4 coincides with a sequence that is a nexus for radiation-induced regulatory events", it has been suggested that exposure to DNA double-strand break-introducing agents "may be one of the factors" mediating autoimmune responses.[22][23]

Endometriosis susceptibility[edit]

There has been speculation that "XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes and alleles . . . might be associated with higher endometriosis susceptibilities and pathogenesis".[24]

Potential use as a cancer biomarker[edit]

In view of the possible associations of XRCC4 polymorphisms with risk of cancer susceptibility (see discussion above), XRCC4 could be used as a biomarker for cancer screening, particularly with respect to prostate cancer, breast cancer, and bladder cancer.[16] In fact, XRCC4 polymorphisms were specifically identified as having the potential to be novel useful markers for "primary prevention and anticancer intervention" in the case of urothelial bladder cancer.[16]

Radiosensitization of tumor cells[edit]

In view of the role of XRCC4 in DNA double-strand break repair, the relationship between impaired XRCC4 function and the radiosensitization of tumor cells has been investigated. For instance, it has been reported that "RNAi-mediated targeting of noncoding and coding sequences in DNA repair gene messages efficiently radiosensitizes human tumor cells".[25]

Potential role in therapeutics[edit]

There has been discussion in the literature comcerning the potential role of XRCC4 in the development of novel therapeutics. For instance, Wu et al. have suggested that since the XRCC4 gene is "critical in NHEJ" and is "positively associated with cancer susceptibility", some XRCC4 SNPs such as G-1394T (rs6869366) "may serve as a common SNP for detecting and predict[ing] various cancers (so far for breast, gastric and prostate cancers . . .)"; and, although further investigation is needed, "they may serve as candidate targets for personalized anticancer drugs".[21] The possibility of detecting endometriosis on this basis has also been mentioned, and this may also possibly lead to the eventual development of treatments.[21][26] In evaluating further possibilites for anticancer treatments, Wu et al. also commented on the importance of “co-treatments of DNA-damaging agents and radiation”.[21] Specifically, Wu et al. noted that the “balance between DNA damage and capacity of DNA repair mechanisms determines the final therapeutic outcome” and “the capacity of cancer cells to complete DNA repair mechanisms is important for therapeutic resistance and has a negative impact upon therapeutic efficacy”, and thus theorized that “[p]harmacological inhibition of recently detected targets of DNA repair with several small-molecule compounds . . . . has the potential to enhance the cytotoxicity of anticancer agents”.[21]

Anti-XRCC4 antibodies[edit]

Anti-XRCC4 antibodies include Alexa Fluor anti-XRCC4 mouse monoclonal antibody ab118008 (4H9), anti-XRCC4 rabbit polyclonal antibody ab157147 (N-terminal), and rabbit polyclonal anti-XRCC4 antibody ab145 (ChIP Grade) (all available from Abcam; Cambridge, MA, USA); phosphospecific antibodies to pS260 and pS318 in XRCC4, raised in sheep against the phosphopeptides: Ser260: SIISSLDVTD and Ser318: AENMSLETLR (phosphoserines underlined); and SAB2102728 (Sigma) anti-XRCC4 rabbit polyclonal antibody (available from Sigma-Aldrich; St. Louis, MO, USA).[27][28] Antibodies to XRCC4 can have a variety of uses, including use in immunoassays to conduct research in areas such as DNA damage and repair, non-homologous end joining, transcription factors, epigenetics and nuclear signaling.[28][29]

History[edit]

Research carried out in the 1980s revealed that a Chinese hamster ovary (CHO) cell mutant called XR-1 was "extremely sensitive" with regard to being killed by gamma rays during the G1 portion of the cell cycle but, in the same research studies, showed "nearly normal resistance" to gamma-ray damage during the late S phase;[30] and in the course of this research, XR-1’s cell-cycle sensitivity was correlated with its inability to repair DNA double-strand breaks produced by ionizing radiation and restriction enzymes.[30][31][32] In particular, in a study using somatic cell hybrids of XR-1 cells and human fibroblasts, Giaccia et al. (1989) showed that the XR-1 mutation was a recessive mutation;[32] and in follow-up to this work, Giaccia et al. (1990) carried out further studies examining the XR-1 mutation (again using somatic cell hybrids formed between XR-1 and human fibroblasts) and were able to map the human complementing gene to chromosome 5 using chromosome-segregation analysis.[33] Giaccia et al, tentatively assigned this human gene the name “XRCC4” (an abbreviation of “X-ray-complementing Chinese hamster gene 4”) and determined that (a) the newly named XRCC4 gene biochemically restored the hamster defect to normal levels of resistance to gamma-ray radiation and bleomycin and (b) the XRCC4 gene restored the proficiency to repair DNA DSBs.[33] Based on these findings, Giaccia et al. proposed that XRCC4 ― as a single gene― was responsible for the XR-1 phenotype.[33]

References[edit]

  1. ^ West CE, Waterworth WM, Jiang Q, Bray CM (October 2000). "Arabidopsis DNA ligase IV is induced by gamma-irradiation and interacts with an Arabidopsis homologue of the double strand break repair protein XRCC4". Plant J. 24 (1): 67–78. doi:10.1046/j.1365-313x.2000.00856.x. PMID 11029705. 
  2. ^ a b c d Oksenych V, Kumar V, Liu X, Guo C, Schwer B, Zha S, Alt FW (February 2013). "Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining". Proc. Natl. Acad. Sci. U.S.A. 110 (6): 2234–9. doi:10.1073/pnas.1222573110. PMC 3568359. PMID 23345432. 
  3. ^ a b Yurchenko V, Xue Z, Sadofsky MJ (March 2006). "SUMO modification of human XRCC4 regulates its localization and function in DNA double-strand break repair". Mol. Cell. Biol. 26 (5): 1786–94. doi:10.1128/MCB.26.5.1786-1794.2006. PMC 1430232. PMID 16478998. 
  4. ^ a b c d e f g h i j k l m n o p q Watson, James (2008). Molecular Biology of the Gene. New York: Cold Spring Harbor Laboratory Press. pp. 148, 265–278. ISBN 978-0-8053-9592-1. 
  5. ^ a b c d e f g Andres SN, Vergnes A, Ristic D, Wyman C, Modesti M, Junop M (February 2012). "A human XRCC4-XLF complex bridges DNA". Nucleic Acids Res. 40 (4): 1868–78. doi:10.1093/nar/gks022. PMC 3287209. PMID 22287571. 
  6. ^ Shao N, Jiang WY, Qiao D, Zhang SG, Wu Y, Zhang XX, Hua LX, Ding Y, Feng NH (2012). "An updated meta-analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies". Cancer Biomark 12 (1): 37–47. doi:10.3233/CBM-120292. PMID 23321468. 
  7. ^ a b c d De Bont R, van Larebeke N (May 2004). "Endogenous DNA damage in humans: a review of quantitative data". Mutagenesis 19 (3): 169–85. doi:10.1093/mutage/geh025. PMID 15123782. 
  8. ^ a b Lieber MR, Lu H, Gu J, Schwarz K (January 2008). "Flexibility in the order of action and in the enzymology of the nuclease, polymerases, and ligase of vertebrate non-homologous DNA end joining: relevance to cancer, aging, and the immune system". Cell Res. 18 (1): 125–33. doi:10.1038/cr.2007.108. PMID 18087292. 
  9. ^ a b Reynolds P, Anderson JA, Harper JV, Hill MA, Botchway SW, Parker AW, O'Neill P (November 2012). "The dynamics of Ku70/80 and DNA-PKcs at DSBs induced by ionizing radiation is dependent on the complexity of damage". Nucleic Acids Res. 40 (21): 10821–31. doi:10.1093/nar/gks879. PMC 3510491. PMID 23012265. 
  10. ^ "Entrez Gene: XRCC4 X-ray repair complementing defective repair in Chinese hamster cells 4". 
  11. ^ Junop MS, Modesti M, Guarné A, Ghirlando R, Gellert M, Yang W (November 2000). "Crystal structure of the Xrcc4 DNA repair protein and implications for end joining". EMBO J. 19 (22): 5962–70. doi:10.1093/emboj/19.22.5962. PMC 305814. PMID 11080143. 
  12. ^ Mari PO, Florea BI, Persengiev SP, Verkaik NS, Brüggenwirth HT, Modesti M, Giglia-Mari G, Bezstarosti K, Demmers JA, Luider TM, Houtsmuller AB, van Gent DC (December 2006). "Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4". Proc. Natl. Acad. Sci. U.S.A. 103 (49): 18597–602. doi:10.1073/pnas.0609061103. PMC 1693708. PMID 17124166. 
  13. ^ a b c d e Wu PY, Frit P, Meesala S, Dauvillier S, Modesti M, Andres SN, Huang Y, Sekiguchi J, Calsou P, Salles B, Junop MS (June 2009). "Structural and functional interaction between the human DNA repair proteins DNA ligase IV and XRCC4". Mol. Cell. Biol. 29 (11): 3163–72. doi:10.1128/MCB.01895-08. PMC 2682001. PMID 19332554. 
  14. ^ Lodish, Harvey (2013). Molecular Cell Biology. New York: W. H. Freeman and Company. pp. 1060–1061, 1068–1076. ISBN 978-1-4292-3413-9. 
  15. ^ Popławski T, Stoczyńska E, Błasiak J (2009). "[Non-homologous DNA end joining--new proteins, new functions, new mechanisms]". Postepy Biochem. (in Polish) 55 (1): 36–45. PMID 19514464. 
  16. ^ a b c d Mittal RD, Gangwar R, Mandal RK, Srivastava P, Ahirwar DK (February 2012). "Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer". Mol. Biol. Rep. 39 (2): 1667–75. doi:10.1007/s11033-011-0906-z. PMID 21617942. 
  17. ^ a b Zhou LP, Luan H, Dong XH, Jin GJ, Ma DL, Shang H (2012). "Association of functional polymorphisms of the XRCC4 gene with the risk of breast cancer: a meta-analysis". Asian Pac. J. Cancer Prev. 13 (7): 3431–6. doi:10.7314/APJCP.2012.13.7.3431. PMID 22994773. 
  18. ^ Cifci S, Yilmaz M, Pehlivan M, Sever T, Okan V, Pehlivan S (November 2011). "DNA repair genes polymorphisms in multiple myeloma: no association with XRCC1 (Arg399Gln) polymorphism, but the XRCC4 (VNTR in intron 3 and G-1394T) and XPD (Lys751Gln) polymorphisms is associated with the disease in Turkish patients". Hematology 16 (6): 361–7. doi:10.1179/102453311X13127324303399. PMID 22183071. 
  19. ^ Mandal RK, Singh V, Kapoor R, Mittal RD (May 2011). "Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population?". Biomarkers 16 (3): 236–42. doi:10.3109/1354750X.2010.547599. PMID 21506695. 
  20. ^ a b Wang JH, Alt FW, Gostissa M, Datta A, Murphy M, Alimzhanov MB, Coakley KM, Rajewsky K, Manis JP, Yan CT (December 2008). "Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching". J. Exp. Med. 205 (13): 3079–90. doi:10.1084/jem.20082271. PMC 2605230. PMID 19064702. 
  21. ^ a b c d e f g Wu CN, Liang SY, Tsai CW, Bau DT (November 2008). "The role of XRCC4 in carcinogenesis and anticancer drug discovery". Recent Pat Anticancer Drug Discov 3 (3): 209–19. doi:10.2174/157489208786242304. PMID 18991789. 
  22. ^ Lee KJ, Dong X, Wang J, Takeda Y, Dynan WS (September 2002). "Identification of human autoantibodies to the DNA ligase IV/XRCC4 complex and mapping of an autoimmune epitope to a potential regulatory region". J. Immunol. 169 (6): 3413–21. doi:10.4049/jimmunol.169.6.3413. PMID 12218164. 
  23. ^ Takeda Y, Dynan WS (November 2001). "Autoantibodies against DNA double-strand break repair proteins". Front. Biosci. 6: D1412–22. doi:10.2741/Takeda. PMID 11689355. 
  24. ^ Hsieh YY, Bau DT, Chang CC, Tsai CH, Chen CP, Tsai FJ (May 2008). "XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes but not XRCC4 intron 3 gene polymorphism are associated with higher susceptibility for endometriosis". Mol. Reprod. Dev. 75 (5): 946–51. doi:10.1002/mrd.20829. PMID 18246529. 
  25. ^ Zheng Z, Ng WL, Zhang X, Olson JJ, Hao C, Curran WJ, Wang Y (March 2012). "RNAi-mediated targeting of noncoding and coding sequences in DNA repair gene messages efficiently radiosensitizes human tumor cells". Cancer Res. 72 (5): 1221–8. doi:10.1158/0008-5472.CAN-11-2785. PMID 22237628. 
  26. ^ Hsieh YY, Bau DT, Chang CC, Tsai CH, Chen CP, Tsai FJ (May 2008). "XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes but not XRCC4 intron 3 gene polymorphism are associated with higher susceptibility for endometriosis". Mol. Reprod. Dev. 75 (5): 946–51. doi:10.1002/mrd.20829. PMID 18246529. 
  27. ^ Roy S, Andres SN, Vergnes A, Neal JA, Xu Y, Yu Y, Lees-Miller SP, Junop M, Modesti M, Meek K (February 2012). "XRCC4's interaction with XLF is required for coding (but not signal) end joining". Nucleic Acids Res. 40 (4): 1684–94. doi:10.1093/nar/gkr1315. PMC 3287172. PMID 22228831. 
  28. ^ a b "Anti-XRCC4 antibody - ChIP Grade (ab145) | Abcam". Abcam. ; "XRCC4 antibody | Western | SAB2102728". Sigma-Aldrich. 
  29. ^ Massip L, Caron P, Iacovoni JS, Trouche D, Legube G (August 2010). "Deciphering the chromatin landscape induced around DNA double strand breaks". Cell Cycle 9 (15): 2963–72. doi:10.4161/cc.9.15.12412. PMID 20714222. 
  30. ^ a b Giaccia A, Weinstein R, Hu J, Stamato TD (September 1985). "Cell cycle-dependent repair of double-strand DNA breaks in a gamma-ray-sensitive Chinese hamster cell". Somat. Cell Mol. Genet. 11 (5): 485–91. doi:10.1007/BF01534842. PMID 3862244. 
  31. ^ Stamato TD, Dipatri A, Giaccia A (August 1988). "Cell-cycle-dependent repair of potentially lethal damage in the XR-1 gamma-ray-sensitive Chinese hamster ovary cell". Radiat. Res. 115 (2): 325–33. doi:10.2307/3577168. PMID 3406371. 
  32. ^ a b Giaccia AJ, Richardson E, Denko N, Stamato TD (January 1989). "Genetic analysis of XR-1 mutation in hamster and human hybrids". Somat. Cell Mol. Genet. 15 (1): 71–7. doi:10.1007/BF01534671. PMID 2916163. 
  33. ^ a b c Giaccia AJ, Denko N, MacLaren R, Mirman D, Waldren C, Hart I, Stamato TD (September 1990). "Human chromosome 5 complements the DNA double-strand break-repair deficiency and gamma-ray sensitivity of the XR-1 hamster variant". Am. J. Hum. Genet. 47 (3): 459–69. PMC 1683886. PMID 1697445. 

Further reading[edit]

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.